Fighting COVID19 with recombinant fully human Antibodies neutralizing SARS-CoV2 to help COVID-19 affected patients
CORAT Therapeutics GmbH develops an innovative therapeutic drug composed of a novel fully human neutralizing antibody against COVID-19, which very efficiently neutralizes SARS-CoV-2 and stops its spread within the human body. Our lead product, COR-101, decreased the virus load in the lung by more than 99 % in the Hamster COVID-19 model, and induced recovery after 2 days, compared to 7 days untreated (more information).
Our goal is to realize our vision of an immunotherapeutic remedy for acute COVID-19 as fast as possible. In contrast to any vaccine, such a drug is dedicated to treat and cure COVID-19 infected patients.
The drug could additionally be used for passive immunization and immediate protection of people exposed to the virus such as people working in the healthcare system or people which have been in contact with infected patients. It could also be used impaired patients or risk groups (people suffering from underlying diseases having a high risk of severe COVID-19 infections.
Towards our goals, a large set of more than 750 different fully human monoclonal antibodies recognising SARS-CoV2 Spike (S) protein has initially been isolated by antibody phage display from human antibody gene libraries obtained from healthy donors and convalescent COVID-19 patients. These antibody candidates underwent a fast track development process to identify the lead molecules with the optimal drug features for a passive vaccine. Innovative and state of the art methods and our large network of scientific experts, supporters and competent contract companies currently work together to manufacture the drug. We aim to achieve first-in-man studies very soon, while keeping all necessary safety and quality requirements for medical use substances in accordance with the respective authorities.
How our passive vaccines work: antibodies can directly block SARS-CoV-2 infection by preventing the attachment of the virus to the human cells. See high resolution of this binding here or in the original publication.
How CORAT antibodies protect
Recombinant human virus-neutralizing antibodies are the active components of our immunotherapy concept (also named “passive vaccine”). Antibodies (immunogobulins, IgG) are molecules made by our own body to protect us against infections.
The CORAT antibody will neutralise SARS-CoV2 directly after injection and so provide protection in exactly the same way like the antibodies of our own body do once we generated them due to an infection or after a vaccination.
The CORAT antibody stops the virus by inhibiting its capacity to enter our cells, so immediately protecting the patients until their own immune system had enough time to their own antibodies. CORAT Therapeutics’ neutralising antibodies are expected to be very well tolerated, because they are fully human proteins like the antibodies we have in our body every day anyway. Due to the long serum half time, a CORAT antibody could be given before infection to protect risk populations or medical care personnel, or after an infection with immediate antiviral effect and long protection until the body had the time to produce enough of its own IgG.